--- title: "Elutia (ELUT) news: going concern and settlement" url: "https://aibio.space/companies/elutia/" publisher: "aibio.space (Biotech Investor Relations News)" summary: "ELUT going concern and settlement news: Elutia closes CIED business sale to Boston Scientific, puts $8 million in escrow, repays SWK loan. Elutia, Inc." --- ELUT Elutia, Inc. NASDAQ · United States # Elutia (ELUT) news ELUT going concern and settlement news Mergers · 2026-08-21 ## [Elutia completes SimpliDerm business sale to Cellution Biologics, receives $7.7 million](https://aibio.space/news/elutia-completes-simpliderm-business-sale-cellution-biologics-receives/) The August 17, 2026 closing leaves the price open to an inventory adjustment and up to $3 million in contingent payments. Elutia says it will focus on NXT-41x and believes it has funding through the first full year of its commercial launch in 2028. ## Latest Elutia news 1. 2025-10-07 Mergers [Elutia closes CIED business sale to Boston Scientific, puts $8 million in escrow, repays SWK loan](https://aibio.space/news/elutia-closes-cied-business-sale-boston-scientific-puts-8-million/) The sale closed October 1, 2025 for $88 million in cash, with $8 million held in escrow. Elutia used about $27.8 million to repay SWK Funding debt, and its 2024 annual report carried a going-concern warning after a net loss of $53.9 million. 2. 2025-10-07 Mergers [Elutia closes $88 million sale of BioEnvelope business to Boston Scientific](https://aibio.space/news/elutia-closes-88-million-sale-bioenvelope-business-boston-scientific/) Elutia sold its EluPro and CanGaroo bioenvelopes for cash. It plans to bring its NXT-41x breast reconstruction product to market in the first half of 2027. 3. 2025-05-08 Financings [Elutia issues 1,105,528 shares to Ligand to settle $2.2 million in royalties](https://aibio.space/news/elutia-issues-1-105-528-shares-ligand-settle-2-2-million-royalties/) Elutia receives no cash from the issuance. In its first-quarter results it said the change reduces cash outflows by $2.2 million in H1 2025. ## Elutia at a glance - **Ticker**: ELUT - **Listing**: NASDAQ - **Country**: United States - **Cash, Jun 30, 2026**: $19.9 million ### Related companies - [Alamar Biosciences](https://aibio.space/companies/alamar-biosciences/) NASDAQ: ALMR - [Cell Source](https://aibio.space/companies/cell-source/) OTC: CLCS - [Manhattan Scientifics](https://aibio.space/companies/manhattan-scientifics/) OTC: MHTX - [Amarantus Bioscience Holdings](https://aibio.space/companies/amarantus-bioscience/) OTC: AMBS - [Oncotelic Therapeutics](https://aibio.space/companies/oncotelic-therapeutics/) OTC: OTLC - [Life Stem Genetics](https://aibio.space/companies/life-stem-genetics/) OTC: LIFS - [Natera](https://aibio.space/companies/natera/) NASDAQ: NTRA - [Tvardi Therapeutics](https://aibio.space/companies/tvardi-therapeutics/) NASDAQ: TVRD ### Also on NASDAQ - [Arvinas](https://aibio.space/companies/arvinas/) ARVN - [TANDEM DIABETES CARE INC](https://aibio.space/companies/tandem-diabetes-care/) TNDM - [TREACE MEDICAL CONCEPTS, INC.](https://aibio.space/companies/treace-medical-concepts/) TMCI - [Biofrontera](https://aibio.space/companies/biofrontera-bfri/) BFRI - [BioStem Technologies](https://aibio.space/companies/biostem-technologies/) BSEM - [BillionToOne](https://aibio.space/companies/billiontoone/) BLLN ## What Elutia does Elutia develops proprietary drug-eluting biomatrix products for surgical reconstruction and related applications, aiming to reduce complications such as infection, migration, erosion, implant rejection and fibrosis. On October 1, 2025 it sold substantially all of the assets of its cardiac implantable electronic device business, including EluPro and CanGaroo, to Boston Scientific Corporation and Cardiac Pacemakers Inc. for an aggregate purchase price of up to $88.0 million in cash. It is now focused on its drug-eluting biomatrix platform. Its lead development programs are NXT-41, a next-generation biologic matrix, and NXT-41x, which adds local antibiotic delivery. Elutia continues to sell SimpliDerm, a human acellular dermal matrix, and its cardiovascular repair portfolio of ProxiCor, VasCure and Tyke through independent sales agents to healthcare facilities. Its headquarters and production space in Gaithersburg, Maryland supports development of NXT-41 and NXT-41x. | Product or program | What it is | Stage | |---|---|---| | NXT-41 | Next-generation biologic matrix designed for consistent handling and scalable manufacturing | lead development program | | NXT-41x | NXT-41 matrix with antibiotics released locally over extended periods | development; requires FDA marketing authorization | | SimpliDerm | Human acellular dermal matrix used in soft tissue reconstruction | sold | | ProxiCor | Cardiovascular repair product in the company’s Cardiovascular segment | sold | Summarised from the company's [10-K filed Mar 13, 2026](https://www.sec.gov/Archives/edgar/data/1708527/000110465926027664/elut-20251231x10k.htm). ## Elutia annual financials | Line | FY2025 | FY2024 | |---|---|---| | Research and development | [$4.2 million](https://www.sec.gov/Archives/edgar/data/1708527/000110465926027664/) | [$3.0 million](https://www.sec.gov/Archives/edgar/data/1708527/000110465926027664/) | | Net income (loss) | [$53.4 million](https://www.sec.gov/Archives/edgar/data/1708527/000110465926027664/) | [-$53.9 million](https://www.sec.gov/Archives/edgar/data/1708527/000110465926027664/) | | Cash from operations | [-$44.8 million](https://www.sec.gov/Archives/edgar/data/1708527/000110465926027664/) | [-$22.7 million](https://www.sec.gov/Archives/edgar/data/1708527/000110465926027664/) | | Cash and equivalents | [$36.4 million](https://www.sec.gov/Archives/edgar/data/1708527/000110465926097292/) | [$13.2 million](https://www.sec.gov/Archives/edgar/data/1708527/000110465926027664/) | Latest balance sheet, Jun 30, 2026 (10-Q): cash and equivalents $19.9 million. Figures as reported to the SEC in XBRL; each one links to its filing. Not adjusted, not investment advice. ## Questions about Elutia Has Elutia issued a going-concern warning? Our latest story on this, dated Oct 7, 2025: "Elutia closes CIED business sale to Boston Scientific, puts $8 million in escrow, repays SWK loan". The story links the filing or release it is based on. [Read the story](https://aibio.space/news/elutia-closes-cied-business-sale-boston-scientific-puts-8-million/). Has Elutia settled a lawsuit? Our latest story on this, dated May 8, 2025: "Elutia issues 1,105,528 shares to Ligand to settle $2.2 million in royalties". The story links the filing or release it is based on. [Read the story](https://aibio.space/news/elutia-issues-1-105-528-shares-ligand-settle-2-2-million-royalties/). What is the ticker symbol of Elutia? Elutia, Inc. trades under the ticker ELUT on NASDAQ. Where is Elutia listed? Elutia, Inc. is listed on NASDAQ. What is the SEC CIK of Elutia? The SEC Central Index Key (CIK) for Elutia, Inc. is 1708527. Its filings are on SEC EDGAR. Which country or territory is Elutia listed under? Our directory records Elutia, Inc. under United States. What does Elutia do? Our directory classifies Elutia, Inc. as: Biotechnology. This is a directory classification, not a description of the pipeline. What is the ISIN of Elutia? The ISIN recorded for Elutia, Inc. is US05479K1060. Does aibio.space cover Elutia? aibio.space lists Elutia, Inc. among 2,820 public biotech companies and publishes its news here as stories appear. Where is Elutia incorporated? SEC records list its state or country of incorporation as DE. What does Elutia develop? Elutia develops proprietary drug-eluting biomatrix products for surgical reconstruction and related applications, aiming to reduce complications such as infection, migration, erosion, implant rejection and fibrosis. On October 1, 2025 it sold substantially all of the assets of its cardiac implantable electronic device business, including EluPro and CanGaroo, to Boston Scientific Corporation and Cardiac Pacemakers Inc. for an aggregate purchase price of up to $88.0 million in cash. What is NXT-41 from Elutia? NXT-41: Next-generation biologic matrix designed for consistent handling and scalable manufacturing Stage: lead development program. What is NXT-41x from Elutia? NXT-41x: NXT-41 matrix with antibiotics released locally over extended periods Stage: development; requires FDA marketing authorization. Is Elutia profitable? Elutia, Inc. reported net income of $53.4 million for the fiscal year ended Dec 31, 2025, and used $44.8 million of cash in operations, per its annual report to the SEC. How much does Elutia spend on research and development? $4.2 million in the fiscal year ended Dec 31, 2025, per its annual report. ## Investor discussion: Elutia Members talk about Elutia (ELUT). Reader posts, not aibio.space reporting, and not investment advice. Rules 1. **Securities violations are strictly forbidden.** No market manipulation, no pump-and-dump, no false or misleading statements, and no inside information. 2. **Say whether you hold the stock.** Every post states long, short or no position. 3. **No paid or sponsored posts.** Do not post for anyone who pays or rewards you. 4. **No buy or sell calls and no price targets.** 5. **No accusations of crime or fraud against named people** unless you link a court filing or a regulator's release that makes them. 6. **No personal details and no spam.** No links at all for your first 7 days as a member. Posts that break the rules may be deleted without notice, and the account restricted or closed. See the [terms](https://aibio.space/terms/#discussion) and the [privacy policy](https://aibio.space/privacy/#discussion). ## Capital-markets timeline Financings, listing notices, splits, legal actions and other investor events at Elutia, newest first. Each line links the filing it comes from. 1. 2026-08-21 Mergers Reported completing an acquisition or a sale of assets. SEC Form 8-K (Items 2.01,7.01,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1708527/000110465926099731/elut-20260817xex99d1.htm) 2. 2026-08-07 Listings Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 3.01,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1708527/000110465926092718/tm2622521d1_8k.htm) 3. 2026-03-04 Listings Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 8.01,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1708527/000110465926023189/elut-20260304xex99d1.htm) 4. 2026-01-02 Listings Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 3.01,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1708527/000110465926000076/elut-20251223x8k.htm) 5. 2025-11-12 Listings Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 3.01,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1708527/000110465925109699/tm2530843d1_8k.htm) 6. 2025-10-07 Mergers Reported completing an acquisition or a sale of assets. SEC Form 8-K (Items 1.01,2.01,7.01,8.01,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1708527/000110465925097561/tm2528122d1_ex99-1.htm) 7. 2025-05-08 Financings Reported a financing. SEC Form 8-K (Items 1.01,2.02,3.02,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1708527/000110465925046155/tm2514493d1_ex99-1.htm) 8. 2025-05-06 Distress Reported the end of a material agreement. SEC Form 8-K (Items 1.02,7.01,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1708527/000110465925045050/tm2514183d1_ex99-1.htm) 9. 2025-04-11 Financings Set up an at-the-market program to sell shares over time. SEC Form 424B5. [Source](https://www.sec.gov/Archives/edgar/data/1708527/000110465925034215/tm259272-4_424b5.htm) 10. 2025-03-18 Financings Set up an at-the-market program to sell shares over time. SEC Form S-3. [Source](https://www.sec.gov/Archives/edgar/data/1708527/000110465925024551/tm259272-1_s3.htm) 11. 2025-02-03 Financings Reported a financing. SEC Form 424B5. [Source](https://www.sec.gov/Archives/edgar/data/1708527/000110465925008291/tm254591-1_424b5.htm) ## Stock chart Price chart and quote supplied by TradingView, delayed as the exchange requires. It loads only if you choose to show it. Information only, not investment advice. [Open NASDAQ:ELUT on TradingView](https://www.tradingview.com/symbols/NASDAQ-ELUT/). ## SEC filings and registration - **SEC name**: Elutia Inc. - **CIK**: 1708527 - **Industry (SIC)**: Biological Products, (No Diagnostic Substances) (2836) - **US tickers**: ELUT (Nasdaq) - **State or country of incorporation**: DE - **Fiscal year ends**: December 31 - **Filer category**:
Emerging growth company - **Business address**: 12510 PROSPERITY DRIVE, SILVER SPRING, MD, 20904 - **Phone**: 240-247-1143 - **Former names**: AZIYO BIOLOGICS, INC. ### Recent filings (8-K and 6-K are the company's own announcements) - [8-K](https://www.sec.gov/Archives/edgar/data/1708527/000110465926099731/elut-20260817x8k.htm) filed 2026-08-21 - [10-Q](https://www.sec.gov/Archives/edgar/data/1708527/000110465926097292/elut-20260630x10q.htm) filed 2026-08-14 - [8-K](https://www.sec.gov/Archives/edgar/data/1708527/000110465926095934/elut-20260813x8k.htm) filed 2026-08-13 - [8-K](https://www.sec.gov/Archives/edgar/data/1708527/000110465926092718/tm2622521d1_8k.htm) filed 2026-08-07 - [8-K](https://www.sec.gov/Archives/edgar/data/1708527/000110465926085061/tm2620864d1_8k.htm) filed 2026-07-20 - [8-K](https://www.sec.gov/Archives/edgar/data/1708527/000110465926074660/elut-20260611x8k.htm) filed 2026-06-16 - [10-Q](https://www.sec.gov/Archives/edgar/data/1708527/000110465926062634/elut-20260331x10q.htm) filed 2026-05-15 - [8-K](https://www.sec.gov/Archives/edgar/data/1708527/000110465926061150/elut-20260514x8k.htm) filed 2026-05-14 Source: [SEC EDGAR](https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0001708527), retrieved October 23, 2026. Shares outstanding is the cover-page figure from the latest periodic report. The SEC does not publish share prices. ## Listing details Elutia, Inc. is a public biotech or pharmaceutical company listed on NASDAQ under the ticker ELUT, recorded under United States. The directory classifies it as Biotechnology. aibio.space tracks 2,820 public biotech companies worldwide and publishes investor news on them. - **Company**: Elutia, Inc. - **Ticker**: ELUT - **Listing**: NASDAQ - **Country or territory**: United States - **Business scope**: Biotechnology - **ISIN**: US05479K1060 - **Last quote in directory**: 2026-10-21 - **Directory source**: [Listing page](https://www.tradingview.com/symbols/NASDAQ-ELUT/) Listing facts come from our company directory, researched on October 22, 2026. A listing record does not certify that a security currently trades. [Tell us about a change](https://aibio.space/reputation/#update). Work at this company? [Claim this page](https://aibio.space/claim/). Published and maintained by aibio.space. Not investment advice. [How we work](https://aibio.space/disclosures/). Who manages this page **This page is managed by aibio.space.** The company does not run, edit or pay for this page. News, desk views and Investor Ranks are written and managed independently by aibio.space under our editorial and analytical judgment. Opinion only, not investment advice. [How we work](https://aibio.space/disclosures/#paid) · [Terms](https://aibio.space/terms/#news) · [Request a correction](https://aibio.space/reputation/#update) --- Source page: https://aibio.space/companies/elutia/. Facts in aibio.space stories are checked against company filings and releases; opinion is labelled. Cite as: aibio.space, "Elutia (ELUT) news: going concern and settlement", 2026-10-31, https://aibio.space/companies/elutia/